Wednesday, April 13th, 2016

Stroke Pipeline Market Companies Involved in Therapeutics Development are AB Science SA, Acorda Therapeutics, Inc., Acticor Biotech, ActiveSite Pharmaceuticals, Inc., advanceCor GmbH, Affibody AB, Amarantus Bioscience Holdings, Inc., Anavex Life Sciences Corp., Angion Biomedica Corp., Antoxis Limited, APT Therapeutics, Inc. (Inactive), ArmaGen,Inc., AstraZeneca Plc, Athersys, Inc., Bayer AG, Bioasis Technologies Inc., Biogen, Inc., BioTime, Inc., Cardax Pharmaceuticals, Inc., Cellular Biomedicine Group, Inc., CHA Bio & Diostech Co., Ltd., CoDa Therapeutics, Inc., D-Pharm Ltd., Daiichi Sankyo Company, Limited, DiaMedica Inc., Digna Biotech, S.L., Dong Wha Pharma Co., Ltd., F. Hoffmann-La Roche Ltd., Fina Biotech, Generon (Shanghai) Corporation Ltd., Genervon Biopharmaceuticals, LLC, Glialogix, Inc., Glucox Biotech AB, Green Cross Corporation, Grifols, S.A., Huons Co., Ltd., Inbiopro Solutions Pvt. Ltd., International Stem Cell Corporation, Jeil Pharmaceutical Co., Ltd., JN-International Medical Corporation, Kolon Life Science, Inc., Laboratoires Pierre Fabre SA, Lacer, S.A., LegoChem Biosciences, Inc, Living Cell Technologies Limited, Luc Therapeutics, Inc., Lumosa Therapeutics Co., Ltd., Mapreg S.A.S., Mast Therapeutics, Inc., Medestea Research & Production S.p.A., MediaPharma s.r.l., Mitsubishi Tanabe Pharma Corporation, Neuralstem, Inc., Neuren Pharmaceuticals Limited, Neuronax SAS, Neurotec Pharma SL, NeuroVive Pharmaceutical AB, New Haven Pharmaceuticals, Inc., New World Laboratories, Inc., NoNO, Inc., Omeros Corporation, Panacea Pharmaceuticals, Inc., PharmatrophiX, Inc., Pharmicell Co., Ltd., Phoenix Biotechnology, Inc., Phylogica Limited, PhytoHealth Corporation, Pozen, Inc., Primary Peptides, Inc., Q Therapeutics, Inc., ReCyte Therapeutics, Inc., RegeneRx Biopharmaceuticals, Inc., Remedy Pharmaceuticals, Inc., ReNeuron Group Plc, SanBio, Inc., Saneron CCEL Therapeutics, Inc., Simcere Pharmaceutical Group, StemCells, Inc., Stemedica Cell Technologies, Inc., Sun Pharmaceutical Industries Limited, SynZyme Technologies, LLC, Targazyme, Inc., The International Biotechnology Center (IBC) Generium, TikoMed AB, vasopharm GmbH, Vicore Pharma AB, Virogenomics, Inc., WhanIn Pharmaceutical Co., Ltd., Xigen SA and Zocere, Inc.

Get discount on this research report at

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects.

Complete research report of 563 pages with TOC is available at


  • The report provides a snapshot of the global therapeutic landscape of Stroke
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Stroke and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Stroke pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Stroke
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


File Library

Contact Profile

ReportsnReports is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect With Us on:  



Twitter: https: //

G+ / Google Plus:



Ritesh Tiwari
P: + 1 888 391 5441


Stroke,Stroke market,Stroke pipeline,Stroke market 2015,Stroke pipeline 2015,Stroke therapeutics




More Formats

View QR Code